BioMarin Pharmaceutical, Inc. (BMRN)

TMFBreakerBeth (84.07) Submitted: 5/17/06 1:37 PM : Start Price: $12.26 BMRN Score: 100.67

'Cause Charly said so. ;)

Report this Post Replies: 0 | Reply | Permalink

bigbubba49 (< 20) Submitted: 8/18/08 10:30 PM : Start Price: $25.76 BMRN Score: 10.60

Biomarin targets diseases caused by genetic defects. Most of these are relatively rare, so there is not a large market, and this makes it less likely that a lot of competitors will get into the business. Also, the nature of the drug creation and te...

Report this Post Replies: 1 | Reply | Permalink

LevMyshkin (58.62) Submitted: 9/15/06 2:16 AM : Start Price: $15.97 BMRN Score: 63.08

A nice niche in a growth industry.

Report this Post Replies: 0 | Reply | Permalink

InvestRx (97.19) Submitted: 10/12/08 8:59 PM : Start Price: $20.33 BMRN Score: 7.66

Who's Next in the Biotech Buyout Frenzy?
The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster the...

Report this Post Replies: 0 | Reply | Permalink

stevanic1970 (51.86) Submitted: 3/25/08 1:19 AM : Start Price: $35.69 BMRN Score: -8.11

Bio stocks are in for a jump and this one has already begun it's rebound. Look for this to push the $40 mark in the next month and possibly even the $50 mark by summer.

Report this Post Replies: 0 | Reply | Permalink

stefaneem (97.37) Submitted: 4/17/08 9:16 PM : Start Price: $33.20 BMRN Score: -1.95

Just following my gut on this one.

Report this Post Replies: 0 | Reply | Permalink

irishmanbob (35.28) Submitted: 3/29/08 11:52 PM : Start Price: $34.90 BMRN Score: -8.59

BMRN has a few products to market with orphan drug status. Understandably, this provides a limited revenue, but can still be quite large. It also gives a fair margin of "freedome from competition", which should provide BMRN a buffer well into the fut...

Report this Post Replies: 0 | Reply | Permalink

ecabiac (65.75) Submitted: 10/07/08 9:37 PM : Start Price: $22.89 BMRN Score: 1.03

P/E Ratio of 985.4 is over 47x industry.


May be over leveraged with 2.52 Debt/Equity and 11.1 Current.


Decent income indicates that this is likely a strong company that is simply overpriced at the moment.

Report this Post Replies: 0 | Reply | Permalink

painterflipper (< 20) Submitted: 5/12/08 5:58 AM : Start Price: $39.14 BMRN Score: -11.17

There will always be illnesses and deseases, therefore treatments- like it or not, will be out there.

Report this Post Replies: 0 | Reply | Permalink

abetens (99.09) Submitted: 4/05/08 2:23 PM : Start Price: $36.97 BMRN Score: 8.66

Their lead drug, Kuvan, is only effective in 20% of subjects with PKU.

Report this Post Replies: 0 | Reply | Permalink